The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE: RBS Into Profit But Sets Aside GBP400 Million For Forex Probe

Fri, 31st Oct 2014 09:23

LONDON (Alliance News) - Royal Bank of Scotland Group PLC Friday reported a swing to third-quarter pretax profit, but results included hundreds of millions of pounds of litigation and conduct costs, relating to matters such as regulators' probe into the foreign exchange markets and a further charge taken for the payment protection insurance scandal.

In a statement, RBS, which is 80%-owned by the UK government, said it made a GBP1.27 billion pretax profit in the quarter ended September 30, compared with a GBP634 million pretax loss in the corresponding quarter last year.

The quarterly performance was supported by net impairment provision releases of GBP801 million, primarily in Ulster Bank and in RBS Capital Resolution, the 'bad bank' it set up to run down capital intensive assets, as RBS benefits from improving economic conditions in the UK and Ireland.

"UK and Ireland are showing signs of growth, and impairment trends are significantly better than we had anticipated at the start of the year," Chief Executive Ross McEwan said in a statement.

However, revenue fell to GBP4.36 billion from GBP4.89 billion, as a rise in net interest income, the difference between what RBS receives in interest on loans and the interest it pays out to savers, was more than offset by a drop in non-interest income.

The quarterly performance was achieved despite the bank setting aside GBP780 million relating to litigation and conduct costs, including GBP400 million for regulators' investigations into alleged manipulation in the foreign exchange market and a further GBP100 million for PPI due to higher-than-expected "reactive" complaint volumes. The PPI mis-selling scandal has now cost RBS more than GBP3.3 billion.

The provisions followed a similar move by rival lender Barclays PLC, which on Thursday made a further GBP170 million provision for PPI and set aside GBP500 million for the foreign exchange probe. On Tuesday, Lloyds Banking Group PLC set aside a further GBP900 million to cover PPI expectations.

McEwan also said RBS is on track to meet its capital targets, with the bank's common equity tier 1 ratio improving by 220 basis points since the year end and 70 basis points in the quarter to 10.8%. RBS is working towards a common equity tier 1 ratio minimum of 12%. In a conference call with journalists, McEwan said RBS is focused on further strengthening its capital position.

"We shouldn't be thinking about dividends until we've got a really good capital build and got some of the bumps in the road out of the way," McEwan said.

RBS's leverage ratio, a simple unweighted ratio of a bank?s equity to a measure of its total un-risk-weighted exposure, designed to guard against weaknesses in banks' ability to model risk, increased to 3.9% from 3.7% over the course of the quarter. The bank has a medium term target of attaining a leverage ratio of between 3.5% and 4.0%, while wanting to maintain a ratio of at least 4.0% in the long-term.

The UK banking sector is awaiting proposals over the leverage ratio at 1400 GMT, when the UK Financial Policy Committee?s review of the leverage ratio will be released. Although the Basel Committee on Banking Supervision has set a provisional leverage ratio of 3%, UK banks could face stricter rules.

"In February I placed trust at the heart of my new strategy for our bank. We have taken the first steps towards that goal, with early progress in making RBS simpler, clearer and fairer," Chief Executive McEwan said in a statement.

RBS also confirmed it will retain control of Ulster Bank, following a strategic review.

"We have confirmed today that Ulster Bank remains a core part of our bank. We have a good market position and believe that, with investment, Ulster Bank can deliver attractive shareholder returns in the future," McEwan said.

However, he also noted the banking group's "long list of conduct and litigation issues" to deal with, adding that RBS has "much, much more to do" to restore our customers' trust.

Those issues include an ongoing investigation being undertaken by UK regulators into an IT crash in 2012 that resulted in considerable delays to customer accounts and payments.

RBS also confirmed it has appointed external headhunters as it seeks a replacement for Chairman Philip Hampton, who will leave the bank during 2015 in order to join GlaxoSmithKline PLC.

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 17:10

Miners, personal goods stocks drag FTSE 100 to two-week low

Burberry slips on rating downgrade

*

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.